Seikagaku Corporation

05/26/2023 | Press release | Distributed by Public on 05/25/2023 19:03

Seikagaku Announces the Topline Results from a Phase III Clinical Study (Additional Study) in the U.S. for SI-6603, a Treatment for Lumbar Disc Herniation